key: cord-1050766-x6ee7zof
authors: Landmesser, Ulf; Lehmann, Irina; Eils, Roland
title: Hyperinflammation as underlying mechanism predisposing patients with cardiovascular diseases for severe COVID-19
date: 2021-04-02
journal: Eur Heart J
DOI: 10.1093/eurheartj/ehab191
sha: 8d3213adac040fd64097aaf9c43b3aff70cf1da1
doc_id: 1050766
cord_uid: x6ee7zof

nan

It was already realized early in the COVID-19 pandemic that patients with cardiovascular disease, such as arterial hypertension, have a higher risk for an adverse course of COVID-19, raising the question of the underlying mechanisms. 1 Furthermore, when it was described that the viral spike (S) glycoprotein mediates viral entry via binding to the angiotensin-converting enzyme 2 (ACE2), 2,3 the question was raised whether therapies acting on the renin-angiotensin system, such as ACE inhibitors (ACEI) or angiotensin receptor blockers (ARBs), could affect the risk of infection or the clinical course of COVID-19. In a recent study, both aspects have been approached by using in-depth single-cell sequencing data of airway samples. 4

Notably, a distinct inflammatory predisposition of different immune cell subtypes relevant to COVID-19 was observed in patients with hypertension that correlated with critical disease progression but was already present before SARS-CoV-2 infection, i.e. in SARS-CoV-2-negative patients with hypertension ( Figure 1 ). 4 Moreover, immune activation in hypertensive patients was largely augmented under COVID-19 providing a novel potential explanation for the adverse course of the disease related to a hyperinflammatory response in these patients with cardiovascular disease. 4 Notably, in the RECOVERY trial treatment with dexamethasone reduced mortality among patients with COVID-19 who were receiving either oxygen alone or invasive mechanical ventilation, 5 supporting the concept that immune dysregulation contributes to the critical clinical course of the disease.

In the single-cell sequencing study of airway samples, no difference in ACE2 expression and initial viral concentration was observed among patients with hypertension or cardiovascular disease. 4 Furthermore, ACE2 expression was not altered in patients receiving ACEI/ARB treatment in both, SARS-CoV-2-positive and -negative patients. 4 These data are in line with observational studies that did not support an increased risk of infection with ACEI/ARB treatmen 6 and further support the ESC recommendation not to interrupt ACEI/ARB treatment in the COVID-19 pandemic. The impact of ACE inhibition or ARB treatment on the clinical course of COVID-19 is currently further examined in several randomized clinical studies.

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Pö hlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19

Dexamethasone in hospitalized patients with Covid-19

Renin-angiotensin-aldosterone system blockers and the risk of Covid-19

We thank Soren Lukassen for his valuable support for the figure of the present article.Conflict of interest: U.L. reports speakers or advisory honorary from Novartis, Amgen, Sanofi, Pfizer, Akcea, and Bayer and research grants from Bayer, Amgen and Novartis. I.L. and R.E. have no disclosures.